MX2011012491A - Administracion continua de cilengitida en tratamientos contra el cancer. - Google Patents
Administracion continua de cilengitida en tratamientos contra el cancer.Info
- Publication number
- MX2011012491A MX2011012491A MX2011012491A MX2011012491A MX2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A
- Authority
- MX
- Mexico
- Prior art keywords
- continuous administration
- cilengitide
- cancer treatments
- therapy
- ligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09006941 | 2009-05-25 | ||
PCT/EP2010/003162 WO2010136168A2 (fr) | 2009-05-25 | 2010-05-25 | Administration continue de ligands d'intégrines pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011012491A true MX2011012491A (es) | 2011-12-14 |
Family
ID=43223150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011012491A MX2011012491A (es) | 2009-05-25 | 2010-05-25 | Administracion continua de cilengitida en tratamientos contra el cancer. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20120130146A1 (fr) |
EP (1) | EP2445534A2 (fr) |
JP (1) | JP2012528079A (fr) |
KR (1) | KR20120104491A (fr) |
CN (1) | CN102448497A (fr) |
AU (1) | AU2010252280A1 (fr) |
BR (1) | BRPI1011206A2 (fr) |
CA (1) | CA2763275A1 (fr) |
CL (1) | CL2011002962A1 (fr) |
EA (1) | EA201101651A1 (fr) |
EC (1) | ECSP11011552A (fr) |
IL (1) | IL216537A0 (fr) |
MX (1) | MX2011012491A (fr) |
NZ (1) | NZ597339A (fr) |
SG (1) | SG176103A1 (fr) |
WO (1) | WO2010136168A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153328A (zh) * | 2010-07-16 | 2013-06-12 | 默克专利股份有限公司 | 肽在乳腺癌和/或骨转移灶的治疗中的用途 |
EP2729180B1 (fr) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os |
CA2856329A1 (fr) | 2011-11-17 | 2013-05-23 | Nencki Institute Of Experimental Biology | Compositions et methodes de traitement du gliome |
US20140341922A1 (en) * | 2011-11-25 | 2014-11-20 | SUN R & D Foundation | Method for Overcoming Tolerance to Targeted Anti-Cancer Agent |
LT3127544T (lt) * | 2014-04-04 | 2021-11-25 | Taiho Pharmaceutical Co., Ltd. | Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis |
US10206871B2 (en) * | 2014-10-14 | 2019-02-19 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
CN111132732B (zh) * | 2017-06-29 | 2021-09-21 | 医视特有限公司 | 增强对靶组织的治疗同时限制对非靶组织的损伤的系统 |
EP3638367A4 (fr) | 2017-08-02 | 2021-07-21 | The University of Chicago | Couches organométalliques nanométriques et nanoplaques organométalliques pour thérapie photodynamique induite par rayons x, radiothérapie, thérapie radiodynamique, chimiothérapie, immunothérapie, et toute combinaison de celles-ci |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991003493A1 (fr) | 1989-08-29 | 1991-03-21 | The University Of Southampton | CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
WO1992010209A1 (fr) | 1990-12-04 | 1992-06-25 | The Wistar Institute Of Anatomy And Biology | Anticorps bifonctionnels et procede de preparation |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5741796A (en) | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
JPH10504808A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
US6008214A (en) | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
WO1996026190A1 (fr) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Antagonistes des recepteurs a l'integrine |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
SI0910563T1 (en) | 1995-06-29 | 2003-10-31 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
CZ203698A3 (cs) | 1995-12-29 | 1999-05-12 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
TR199801254T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r� antagonistleri. |
CA2241724A1 (fr) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Antagonistes du recepteur de vitronectine |
SK282894B6 (sk) | 1996-03-20 | 2003-01-09 | Hoechst Marion Roussel | Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú |
AU720758B2 (en) | 1996-04-10 | 2000-06-08 | Merck & Co., Inc. | Alphavbeta3 antagonists |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
AU2438297A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
JP2002515036A (ja) | 1996-05-31 | 2002-05-21 | ザ スクリップス リサーチ インスティテュート | α▲下V▼β▲下5▼媒介血管形成の抑制に有用な方法および組成物 |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
EP0934305A4 (fr) | 1996-08-29 | 2001-04-11 | Merck & Co Inc | Antagonistes de l'integrine |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
EP0946180A4 (fr) | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | Procede de stimulation de la formation osseuse |
AU717283B2 (en) | 1996-10-30 | 2000-03-23 | Merck & Co., Inc. | Integrin antagonists |
EP0946165B1 (fr) | 1996-10-30 | 2003-04-09 | Merck & Co., Inc. | Antagonistes de l'integrine |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
CA2272090A1 (fr) | 1996-12-09 | 1998-06-18 | Matthew J. Fisher | Antagonistes de l'integrine |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
AU729869B2 (en) | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
WO1999005107A1 (fr) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Antagonistes du recepteur de vitronectine |
EP1007051A4 (fr) | 1997-08-04 | 2001-08-29 | Smithkline Beecham Corp | Antagonistes du recepteur de l'integrine |
JP2001514253A (ja) | 1997-09-04 | 2001-09-11 | スミスクライン・ビーチャム・コーポレイション | インテグリンレセプターアンタゴニスト |
PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
TR200000792T2 (tr) | 1997-09-24 | 2000-09-21 | Smithkline Beecham Corporation | Vitronektin reseptör antagonistleri. |
IL135188A0 (en) | 1997-09-24 | 2001-05-20 | Smithkline Beecham Corp | Vitronectin receptor antagonist |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
TR200001752T2 (tr) | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | Entegrin reseptör antagonistleri |
ATE299023T1 (de) | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrinrezeptor antagonisten |
AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
HUP0100397A3 (en) | 1997-12-17 | 2002-10-28 | Merck & Co Inc | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
CN1168741C (zh) | 1998-01-23 | 2004-09-29 | 默克专利股份有限公司 | 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用 |
AU747784B2 (en) | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
WO2000009503A1 (fr) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Antagonistes de recepteurs d'integrine |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
WO2000038730A2 (fr) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques |
DE60035779T2 (de) | 1999-06-02 | 2008-04-30 | Merck & Co., Inc. | Alpha v integrin-rezeptor antagonisten |
JP2004509643A (ja) | 2000-09-29 | 2004-04-02 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | アルキル化剤を用いた化学療法による治療に対する臨床反応を予測する方法 |
CN101370522A (zh) * | 2006-01-18 | 2009-02-18 | 默克专利有限公司 | 使用整联蛋白配体治疗癌症的特别疗法 |
PL2101805T3 (pl) * | 2007-01-18 | 2013-04-30 | Merck Patent Gmbh | Ligandy integryn do stosowania w leczeniu nowotworów |
-
2010
- 2010-05-25 WO PCT/EP2010/003162 patent/WO2010136168A2/fr active Application Filing
- 2010-05-25 JP JP2012511202A patent/JP2012528079A/ja active Pending
- 2010-05-25 CA CA2763275A patent/CA2763275A1/fr not_active Abandoned
- 2010-05-25 SG SG2011084381A patent/SG176103A1/en unknown
- 2010-05-25 MX MX2011012491A patent/MX2011012491A/es not_active Application Discontinuation
- 2010-05-25 AU AU2010252280A patent/AU2010252280A1/en not_active Abandoned
- 2010-05-25 KR KR1020117030945A patent/KR20120104491A/ko not_active Application Discontinuation
- 2010-05-25 EA EA201101651A patent/EA201101651A1/xx unknown
- 2010-05-25 US US13/322,391 patent/US20120130146A1/en not_active Abandoned
- 2010-05-25 BR BRPI1011206A patent/BRPI1011206A2/pt not_active Application Discontinuation
- 2010-05-25 NZ NZ597339A patent/NZ597339A/xx not_active IP Right Cessation
- 2010-05-25 CN CN2010800227000A patent/CN102448497A/zh active Pending
- 2010-05-25 EP EP20100721342 patent/EP2445534A2/fr not_active Withdrawn
-
2011
- 2011-11-22 IL IL216537A patent/IL216537A0/en unknown
- 2011-11-24 CL CL2011002962A patent/CL2011002962A1/es unknown
- 2011-12-23 EC EC2011011552A patent/ECSP11011552A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010136168A8 (fr) | 2011-09-22 |
EP2445534A2 (fr) | 2012-05-02 |
US20120130146A1 (en) | 2012-05-24 |
SG176103A1 (en) | 2011-12-29 |
CA2763275A1 (fr) | 2010-12-02 |
KR20120104491A (ko) | 2012-09-21 |
JP2012528079A (ja) | 2012-11-12 |
NZ597339A (en) | 2013-10-25 |
CL2011002962A1 (es) | 2012-06-01 |
WO2010136168A2 (fr) | 2010-12-02 |
BRPI1011206A2 (pt) | 2016-03-15 |
WO2010136168A3 (fr) | 2011-07-07 |
IL216537A0 (en) | 2012-02-29 |
ECSP11011552A (es) | 2012-01-31 |
AU2010252280A1 (en) | 2012-01-19 |
CN102448497A (zh) | 2012-05-09 |
EA201101651A1 (ru) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011012491A (es) | Administracion continua de cilengitida en tratamientos contra el cancer. | |
WO2007084670A3 (fr) | Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer | |
WO2009010287A3 (fr) | Thérapie spécifique et médicament mettant en œuvre des ligands d'intégrine pour le traitement du cancer | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
IN2014DN11099A (fr) | ||
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
WO2009140675A3 (fr) | Thérapie combinée comportant un alcaloïde antitumoral | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab | |
WO2015038896A3 (fr) | Utilisation de wilforlide a pour surmonter la résistance à la chimiothérapie | |
WO2013096335A8 (fr) | Administration d'un antagoniste de l'intégrine alpha-5-bêta 1 afin de lutter contre l'angiogenèse et de traiter le cancer | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
WO2007082742A8 (fr) | Thérapie combinée du cancer par perfusion d'organes isolés | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
WO2010057596A3 (fr) | Nouvelle thérapie et médicament utilisant des ligands d'intégrine pour traiter un cancer | |
WO2008039525A3 (fr) | Procédés de traitement du cancer au moyen d'antagonistes de cadhérine combinés à des agents anticancéreux | |
MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
WO2012158776A3 (fr) | Thérapie d'association pour le traitement du cancer | |
NZ742470A (en) | Combination therapy for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |